OASISplus
36 evidence topics · 4 sources
Objective
Open-label extension cohort objective
“The majority of patients enrolled in OASIS-HAE (83/90, 92.2%) rolled over into the open-label extension (OLE) cohort of the ongoing OASISplus study (NCT05392114), which is designed to evaluate the long-term safety and efficacy of donidalorsen treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort objective
“The Switch cohort of the OASISplus study (NCT05392114) evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registered study dates and enrollment status
| Field | Reported value |
|---|---|
| Study start | “2022-07-13” |
| Primary completion, estimated | “2026-12” |
| Study completion, estimated | “2027-03” |
| Recruitment status | “Active, not recruiting” |
Data cutoff for the year 1 analyses
“This prespecified analysis of the ongoing OASISplus study reports results for patients who completed the OLE through Week 52 (including 28 additional days of follow-up, defined as the on-treatment period) as of a January 27, 2025 data cut.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OASISplus is an ongoing, global, open‐label study designed to evaluate the long‐term safety and efficacy of donidalorsen 80 mg administered SC in patients with HAE‐C1INH‐Type1 and HAE‐C1INH‐Type2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(data cutoff date: January 27, 2025)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Open-label, single-group design with two cohorts
“OASISplus is an ongoing multicenter, phase 3 study composed of 2 cohorts: a de novo cohort of patients who switched from prior LTPs to donidalorsen 80 mg Q4W (Switch cohort), and an OLE cohort of patients who rolled over from the OASIS-HAE study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Open-label extension cohort: rollover from OASIS-HAE
“Patients were eligible to enroll in the OLE if they successfully completed the OASIS-HAE study or if they had five or more attacks/month for two consecutive months after Week 4 of OASIS-HAE, in which case they could rollover early into the OLE and receive donidalorsen Q4W” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: age and stable prior prophylaxis
“the Switch cohort included adults and adolescents aged ≥ 12 years on stable prophylactic doses of plasma‐derived or recombinant C1INH via SC or intravenous (IV) administration, lanadelumab, or berotralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: exclusions for concomitant medicines and prior oligonucleotides
Treatment
Open-label extension cohort: assignment to every-4-week or every-8-week dosing
“Patients who received donidalorsen 80 mg or placebo Q4W in OASIS-HAE received donidalorsen 80 mg Q4W in OASISplus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received donidalorsen 80 mg or placebo Q8W in OASIS-HAE received donidalorsen 80 mg Q8W in OASISplus, unless they were not attack-free during the last 8 weeks (Weeks 16–24) in OASIS-HAE, in which case they received donidalorsen Q4W in OASISplus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: transition algorithm from prior prophylaxis
“patients were switched from their prior LTP administered during the baseline period to donidalorsen 80 mg administered SC Q4W with no washout period using a prespecified algorithm that was designed to minimize HAE attacks during the switching process” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received prior lanadelumab received their last dose 14 ± 3 days prior to the first dose of donidalorsen on Day 1 of the study, and patients who received prior berotralstat or C1INH continued the treatment for 14 ± 3 days after Day 1 of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using treatment-emergent adverse event incidence as the primary endpoint
Primary endpoint: incidence and severity of treatment-emergent adverse events
Secondary endpoints: attack rate and angioedema quality of life
“Rates of HAE attacks were time-normalized per every 4-week period (28 days), also termed monthly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AE-QoL is a validated, 17-item, disease-specific, self-administered questionnaire with four domains calculated using a scale of 0 to 100, with lower scores indicating better QoL, and a minimal clinically important difference of ≥6 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: attack-rate baseline measured on prior prophylaxis
Exploratory endpoint: disease control on the Angioedema Control Test
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Population | Participants |
|---|---|
| Actual enrollment, both cohorts | “154” |
Open-label extension cohort
“The OLE cohort included 83 patients (Q4W, n=69 [83%]; Q8W, n=14 [17%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No formal sample size calculations were performed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sample size for the OLE cohort was dictated by the number of patients enrolled in the OASIS-HAE study and their eligibility for the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort by prior prophylactic treatment
“A total of 65 patients were enrolled in the original cohort, and of these, 64 (98.5%) patients received at least one dose of donidalorsen (prior lanadelumab, n = 31; prior berotralstat, n = 11; prior C1INH, n = 22 [SC, n = 15; IV, n = 7])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Switch cohort sample size was instead determined per clinical assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Open-label extension cohort: safety and full analysis sets
“results were summarized with descriptive statistics including observed mean, median, patient numbers, and percentages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All endpoints were analyzed using data from the safety and full analysis sets, both defined as all patients who received at least one dose of donidalorsen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: descriptive analysis without a comparator group
“As OASISplus was an open‐label study in which all patients received donidalorsen, no comparator group and no formal sample size calculations were performed to address group differences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety set was used for the primary outcome and all safety analyses. The efficacy endpoints were summarized using descriptive statistics in the full analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Open-label extension cohort: completion and discontinuation at year 1
“As of the data cutoff date (January 27, 2025), 75 patients (90%) completed Week 52 in the OLE study. Eight patients (10%) discontinued treatment early due to voluntary withdrawal (n = 4), AEs (n = 3), or pregnancy (n = 1; Supplemental Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“six patients changed from donidalorsen Q8W in OASIS-HAE to Q4W dosing in OASISplus, and 19 patients from the OASIS-HAE placebo group were assigned to receive donidalorsen Q4W” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: completion and discontinuation at year 1
“54 (83.1%) patients completed 1 year of treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 11 (16.9%) patients discontinued donidalorsen treatment, including 8 (12.3%) patients who switched from lanadelumab and 3 (4.6%) patients who switched from SC or IV C1INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who received lanadelumab before switching to donidalorsen, the most common reason for treatment discontinuation was lack of efficacy (n = 4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patients who received prior berotralstat therapy discontinued treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Open-label extension cohort: demographics and baseline attack rate
| Characteristic, total (N=83) | Reported value |
|---|---|
| Age, years, mean (SD) | “37 (14)”View highlighted excerpt for this quote |
| Age 12 to 17 years, n (%) | “7 (8.4)”View highlighted excerpt for this quote |
| Female, n (%) | “45 (54.2)”View highlighted excerpt for this quote |
| White, n (%) | “76 (91.6)”View highlighted excerpt for this quote |
| Baseline HAE attack rate, mean (SD) | “3.4 (2.1)”View highlighted excerpt for this quote |
Switch cohort: demographics and baseline attack rate on prior prophylaxis
| Characteristic, total (N=64) | Reported value |
|---|---|
| Age, years, mean (SD) | “42 (15)”View highlighted excerpt for this quote |
| Age 12 to 17 years, n (%) | “4 (6.3)”View highlighted excerpt for this quote |
| Female, n (%) | “38 (59.4)”View highlighted excerpt for this quote |
| White, n (%) | “57 (89.1)”View highlighted excerpt for this quote |
| Baseline HAE attack rate, mean (SD) | “0.9 (1.3)”View highlighted excerpt for this quote |
Efficacy results
Open-label extension cohort: reduction in attack rate from OASIS-HAE baseline, weeks 0 to 52
“The mean reduction in HAE attack rate over the 52-week OLE was 94% (median, 98%) in the Q4W group (including patients who moved from Q8W dosing in OASIS-HAE to Q4W in the OLE) and 95% (median, 96%) in the donidalorsen Q8W group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This corresponded to a reduction in mean (SD) time-normalized monthly HAE attack rate from 3.5 (2.13) and 2.9 (2.06) at baseline to 0.3 (0.45) and 0.1 (0.10) over Weeks 0 to 52 in the Q4W and Q8W dosing groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension cohort: attack-free participants, weeks 4 to 52
Switch cohort: change in attack rate from baseline on prior prophylaxis, weeks 0 to 52
“Overall, HAE attack rates decreased by 67.6% from a mean (SD) of 0.85 (1.3) at baseline (on their prior HAE prophylactic therapy) to 0.28 (0.4) over the treatment period through 1 year (Weeks 0–52) of the study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who switched from lanadelumab experienced a 63.9% decrease, patients who switched from berotralstat experienced an 83.1% decrease, and patients who switched from C1INH experienced a 50.7% decrease in HAE attack rate from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Open-label extension cohort: AE-QoL and disease control at week 52
“The mean (SD) reduction from baseline in AE-QoL total score at Week 52 was 27.8 (16.1) points overall, 28.1 (15.7) points in the Q4W group, and 26.7 (18.2) points in the Q8W group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“68 of 70 (97%) patients with an AECT evaluation at both OASIS-HAE baseline and OASISplus Week 52 reported well-controlled disease (AECT score ≥10)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: AE-QoL, disease control, and treatment satisfaction at week 52
“AE‐QoL total score improved by a mean (SD) of 12.2 (17.6) points from baseline to Week 52 in the overall population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, after 52 weeks of treatment with donidalorsen, 90.4% of patients had well‐controlled disease (prior lanadelumab, n/N = 18/22 [81.8%]; prior berotralstat, n/N = 10/10 [100%]; prior C1INH, n/N = 19/20 [95.0%]; Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall mean (SD) global satisfaction domain score on the TSQM‐II improved from 75.7 (21.5) at baseline to 89.4 (15.3) at Week 52” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Open-label extension cohort: treatment-emergent adverse events at year 1
| Event, total (N=83) | Participants, n (%) |
|---|---|
| Any TEAE | “75 (90.4)”View highlighted excerpt for this quote |
| TEAE related to study drug | “22 (26.5)”View highlighted excerpt for this quote |
| TEAE leading to discontinuation | “3 (3.6)”View highlighted excerpt for this quote |
| Any serious TEAE | “7 (8.4)”View highlighted excerpt for this quote |
Open-label extension cohort: serious events, liver enzymes, and bleeding
“Seven (8%) patients, all of whom received donidalorsen Q4W, reported serious AEs; none were considered drug related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One patient in the Q4W group died by suicide, considered unrelated to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the other had a 30-day persistence of alanine aminotransferase levels at >5 times the upper limit of normal (ULN) with normal blood bilirubin concentration that resolved after treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no major bleeding events or treatment-related trends in activated partial thromboplastin time observed during the treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension cohort: hypersensitivity reaction after year 1
“one patient experienced a serious type 1 hypersensitivity reaction characterized by rash, dyspnea, perioral swelling, and chest pain after receiving the 29th dose of donidalorsen Q4W (being on this regimen for approximately 2.5 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Switch cohort: treatment-emergent adverse events at year 1
| Event, total (N=64) | Participants, n (%) |
|---|---|
| Any TEAE | “56 (87.5)”View highlighted excerpt for this quote |
| TEAE related to study drug | “24 (37.5)”View highlighted excerpt for this quote |
| TEAE leading to discontinuation | “1 (1.6)”View highlighted excerpt for this quote |
| Any serious TEAE | “1 (1.6)”View highlighted excerpt for this quote |
Switch cohort: most common treatment-related adverse events
“The most common treatment‐related AEs occurring in more than 5% of the overall population were injection‐site erythema (10.9%), injection‐site pruritus (10.9%), injection‐site pain (7.8%), and fatigue (7.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity in the open-label extension
Study limitations
Summary
OASISplus is an open-label study with no comparator group, and both cohort publications summarized outcomes with descriptive statistics and no formal sample size calculation.
The open-label extension cohort enrolled 83 of the 90 OASIS-HAE participants (69 receiving donidalorsen every 4 weeks and 14 every 8 weeks). Participants continued every-8-week dosing only if they had been attack-free during the last 8 weeks of OASIS-HAE, so the every-8-week group of 14 participants was selected for response. The 94% and 95% reductions are measured from the OASIS-HAE baseline, before any prophylaxis in that trial.
The Switch cohort dosed 64 participants who had been receiving lanadelumab (31), berotralstat (11), or C1 inhibitor (22). Its attack-rate baseline was the screening period on the prior prophylactic treatment (mean 0.85 attacks per month), so the 67.6% reduction is a within-participant comparison with continued prior prophylaxis, without randomization or blinding. Eleven participants (16.9%) discontinued during the first year, including 4 who had switched from lanadelumab and discontinued for lack of efficacy. The subgroups by prior therapy contain 11 to 31 participants, which limits precision for comparisons between them.
In both cohorts, 89.1% to 91.6% of participants were White. The registry lists an actual enrollment of 154 participants across the study, and the two cohort publications report 83 and 65 participants enrolled. The year 1 publications report data through January 27, 2025, and the registry lists treatment for up to 157 weeks, with primary completion estimated for December 2026.